Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have received an average rating of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.7143.

Several equities analysts recently commented on the stock. UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, June 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target on the stock. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $23.00 in a research report on Monday, May 12th.

Teva Pharmaceutical Industries Trading Down 1.7%

TEVA stock opened at $18.14 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The company’s 50-day simple moving average is $16.76 and its 200 day simple moving average is $16.28. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a market capitalization of $20.81 billion, a PE ratio of -113.38, a price-to-earnings-growth ratio of 1.09 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. During the same period in the prior year, the company posted $0.61 earnings per share. Teva Pharmaceutical Industries’s revenue was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Matthew Shields sold 6,206 shares of the company’s stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president directly owned 9,989 shares of the company’s stock, valued at $170,012.78. This represents a 38.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 65,001 shares of company stock valued at $996,958 over the last quarter. 0.55% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall & Sterling Wealth Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter worth about $44,000. Advisors Asset Management Inc. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $41,000. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at approximately $39,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth approximately $43,000. Finally, Sound Income Strategies LLC grew its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.